Growth Hormone Deficiency Market Qualitative Insights on Application & Outlook by Size, Share, Future Growth

Posted by Sanyukta K on August 17th, 2022

Growth hormone deficiency has become a major problem for the health care industry, and the most common cause is believed to be traumatic brain injury. This condition is marked with many symptoms, such as decreased energy levels, decreased muscle strength, altered body composition, osteoporosis, insulin resistance, and lipid abnormalities including high LDL cholesterol.

Explore More Insights@ https://www.alliedmarketresearch.com/request-toc-and-sample/12691

Human growth hormone (hGH) or somatotropin is a peptide hormone responsible for cell regeneration, growth stimulation and cell regeneration. Human growth hormone (GH) deficiency occurs when the pituitary gland cannot synthesize sufficient concentrations of hGH. This deficiency is treated by administering recombinant HGH subcutaneously. A variety of genetic disorders, including Turner syndrome and Prader-Willi syndrome, can cause growth hormone deficiency in humans, leading to reduced average height and delayed puberty.

Key Benefits of the Report

• This study presents the analytical depiction of the growth hormone deficiency along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
• The current market is quantitatively analyzed from 2020 to 2030 to highlight the market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Introduction of novel therapies as well as strong pipeline and R&D investment growth drive the market growth. Increase in growth hormone deficiency disorders and growth in the use of growth hormone to control aging are attributed to the growth of the market. In addition, increasing awareness of the treatment process and increase in neuropsychiatric cases is driving the human growth hormone market.

Aeterna is currently in the early stage of clinical safety as well as efficacy study, which focuses on analyzing Macimorelin for detection of CGHD. November 2020, Aeterna teamed up with Novo Nordisk with the aim to boost the application scope of macimorelin that helps diagnose growth hormone deficiency, which is childhood onset. The company believes that this area is considerably untapped, and therefore needs to explore the unmet needs.

Key Market Players

Novo Nordisk A/S Pfizer, Inc, Eli Lilly and Company, Novartis AG, Merck KGaA, Roche, Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, Ipsen, Ferring B.V.,